The authors describe an anomalous post-infarctual evolution, already revealed by Sotgiu in 1959 and defined the’ postinfarctual anedematous syndrome’ (SAPI). The syndrome, present in about 12% of MI, demonstrates a clinical picture characterized by a global hypometabolism, absence of edema and state of continuous sub-collapse; an endocrine picture characterized by a corticomedullary adrenal, thyroid and hypophisis hypoactivity. The results confirm that, in contrast to other myocardial infarction cases, in patients with SAPI low values of cortisol, aldosterone and catecholamines exist, with alteration of the glycocorticoid and adrenergic amine circadian-biorhythm. The pharmacodynamic tests, demonstrating the integrity of the adrenal gland, have revealed an alteration of the hypothalamic-pituitary function. According to the authors, the occurrence of SAPI might be interpreted on the basis of a particular vulnerability of the hypothalamic-pituitary system (often depending upon the senile age of the subjects) which is probably amplified by the stress created by the myocardial necrosis.

Keywords:
Circadian rhythms, Catecholamines, Cortisol, Myocardial infarction, Post-infarctual anedematous syndrome, Aldosterone, Tetrahydroaldosterone, Stress
This content is only available via PDF.
© 1971 S. Karger AG, Basel
1971
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.